Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
7.55
+0.06 (0.80%)
At close: Aug 22, 2025, 4:00 PM
7.78
+0.23 (3.05%)
After-hours: Aug 22, 2025, 7:35 PM EDT
Trevi Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts that cover Trevi Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $19.35, which forecasts a 156.29% increase in the stock price over the next year. The lowest target is $7.00 and the highest is $27.
Price Target: $19.35 (+156.29%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Trevi Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
---|---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
Buy | 2 | 2 | 2 | 2 | 3 | 4 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 8 | 8 | 8 | 8 | 9 | 10 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Morgan Stanley | Morgan Stanley | Buy Initiates $18 | Buy | Initiates | $18 | +138.41% | Aug 21, 2025 |
Raymond James | Raymond James | Strong Buy Maintains $29 → $27 | Strong Buy | Maintains | $29 → $27 | +257.62% | Aug 8, 2025 |
Needham | Needham | Strong Buy Maintains $24 → $22 | Strong Buy | Maintains | $24 → $22 | +191.39% | Aug 8, 2025 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $25 | Buy | Initiates | $25 | +231.13% | Jul 1, 2025 |
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $21 | Strong Buy | Maintains | $21 | +178.15% | Jun 2, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.43
from -0.47
EPS Next Year
-0.53
from -0.43
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | n/a | 26.6M | ||
Avg | n/a | n/a | 2.9M | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.32 | -0.27 | -0.20 | ||
Avg | -0.43 | -0.53 | -0.72 | ||
Low | -0.50 | -0.68 | -1.30 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.